DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville, MD 20857

ANDA 78-065

Par Pharmaceutical, Inc.
Attention: Linda Kulick
Sr. Associate, Regulatory Affairs
One Ram Ridge Road
Spring Valley, NY 10977

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 20, 2005, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Propranolol Hydrochloride Extended-release Capsules USP, 60 mg, 80 mg, 120 mg and 160 mg.

Reference is also made to your amendments dated February 28, August 25, November 10, and December 27, 2006; January 5, and January 11, 2007.

We have completed the review of this ANDA and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved. The Division of Bioequivalence has determined your Propranolol Hydrochloride Extended-release Capsules USP, 60 mg, 80 mg, 120 mg and 160 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Inderal LA, Propranolol Hydrochloride Extended-release Capsules USP, 60 mg, 80 mg, 120 mg and 160 mg, respectively, of Wyeth Pharmaceuticals Inc.

Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application. The "interim" dissolution specifications are as follows:

Acid Stage: The dissolution testing is conducted in 900 mL of pH 1.2 Buffer for 1.5 hours.

Buffer Stage: The dissolution testing is conducted in 900 mL

of pH 6.8 Buffer for 24 hours.

The test product should meet the USP specifications for Test 1 as follows:

1.5 hours NMT ---
4 hours -----%
8 hours ------
14 hours ------
24 hours -------

The "interim" dissolution test(s) and tolerances should be finalized by submitting dissolution data for the first three production size batches. Data should be submitted as a Special Supplement - Changes Being Effected when there are no revisions to the "interim" specifications or when the final specifications are tighter than the "interim" specifications. In all other instances, the information should be submitted in the form of a Prior Approval Supplement.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed

Form FDA 2253 at the time of their initial use.

Sincerely yours,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Gary Buehler

1/26/2007 04:45:29 PM